← Library
Prescription-only medicine. This page is educational information only. Do not use without a licensed prescriber.
IndexedBuilt automatically from public databases on 2026-09-30. Not yet hand-reviewed by PLOBT.How this works →

Bivalirudin

FDA approved · Rx

Direct thrombin inhibitor

Also known as: Angiomax, bivalirudina, bivalirudine, bivalirudinum, BG-8967, BG8967, Hirulog-1, Angiomax RTU

Evidence score
95/ 100
Strong evidence

Strong, human-grade evidence

  • Regulatory standing. FDA-approved prescription medicine
  • Human trials. Backed by controlled human studies
  • Registered human trials. 92 registered studies on ClinicalTrials.gov, most advanced Phase 4
  • 2 cited sources. Includes primary / regulatory sources

Computed with the same four public criteria as every profile. The human-evidence grade on an indexed profile is set automatically and may change when it is hand-reviewed. It is not a safety score, not a purity rating, and not medical advice, and not a claim that this compound treats, cures, or prevents any condition.

What it is

Bivalirudin is a synthetic 20-amino-acid peptide modeled on hirudin, the anticoagulant found in medicinal leech saliva. It binds directly and reversibly to thrombin, blocking its role in forming blood clots, and is given intravenously in hospital settings.

What the evidence shows

Automatic summaryHuman trials

Bivalirudin is FDA-approved for use as an anticoagulant in patients undergoing percutaneous coronary intervention (PCI), including those with or at risk of heparin-induced thrombocytopenia. It has a large human evidence base, with about 92 registered trials reaching Phase 4 and nearly 2,000 published papers, though its comparative benefits versus heparin in some settings remain debated.

Key facts

Molecular formula
C98H138N24O33
Molecular weight
2180.3 g/mol
FDA approval
Confirmed on openFDA

Registered human trials

Live from ClinicalTrials.gov, refreshed daily.

92registered studies
Phase 4most advanced phase
42completed (sample)
6recruiting (sample)

Bivalirudin With Prolonged Full Dose Infusion Versus Heparin Alone During Emergency PCI

CompletedNCT03822975

Bivalirudin Plus Stenting in Long Lesion to Avoid Periprocedural Myocardial Necrosis Trial

Phase 3UnknownNCT01555658

Comparison of Anticoagulation Prolongation vs. no Anticoagulation in STEMI Patients After Primary PCI

Phase 4CompletedNCT03664180

Ticagrelor vs Clopidogrel in Non-ST Elevation Acute Coronary Syndrome Patients Undergoing PCI With Bivalirudin.

Phase 4TerminatedNCT02052635

Published literature

Live from Europe PMC. This is how much has been published, not how much is proven in humans.

1,948papers referencing Bivalirudin

Bivalirudin during primary PCI in acute myocardial infarction.

N Engl J Med2008

Bivalirudin for patients with acute coronary syndromes.

N Engl J Med2006

Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial.

JAMA2003

Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Chest2012

Sources

Risks, side effects and study doses are only published on hand-reviewed profiles. Want this one reviewed, or spotted something wrong? Tell us.